Loading...
01/11 03:34
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a generally positive outlook with strong revenue growth and reduced losses. The Q&A section reveals favorable feedback on new products and strategic initiatives, although some management responses lacked clarity. The strategic partnership focus and cash infusion from a private placement support growth prospects. Despite slight gross margin decline, the overall sentiment remains positive, driven by significant revenue growth and operational improvements. The absence of market cap information limits the prediction's precision, but the positive indicators suggest a stock price increase in the short term.
Net Sales $9.2 million, a 42% increase compared to Q1 2024 and an 11% sequential gain over Q4 2024. This growth is attributed to the adoption of TriNav in new accounts, increased utilization of existing accounts, and the expansion of the salesforce.
Gross Margin 84%, slightly down from 85% in Q1 2024. The decrease is due to reduced factory volumes associated with a factory clean room expansion.
R&D Expenses $3.3 million, a decrease of 44% from Q1 2024. The reduction is expected to continue due to the completion of nelitolimod patient enrollment in all PERIO studies.
G&A Expenses $5 million, an increase of over 7% compared to Q4 2024, primarily due to the timing of audit and legal expenses.
Operating Losses $7.3 million, compared to losses of $11.7 million in Q1 2024. The decrease in losses is attributed to increased sales and reduced R&D expenses.
Adjusted EBITDA Losses $5.5 million, compared to losses of $10.4 million in Q1 2024. The decrease is primarily due to increased sales, reduced R&D expenses, and higher non-cash stock compensation expense.
Cash and Cash Equivalents $13 million at quarter end, with an additional $22 million raised in gross proceeds from a private placement after the quarter end, providing sufficient liquidity to fund operations throughout 2025.
New Product Launches: Launched TriNav Large and TriGuide, expanding PEDD into larger vessels.
Product Innovation: Initiating full launch of TriNav Flex, which improves trackability for interventional radiologists.
Market Expansion: Gained further penetration in the liver embolization market, increasing unique ordering counts by 39%.
Reimbursement Progress: Received a new HCPCS code (C8004) from CMS for mapping procedures using TriNav, doubling reimbursable uses.
Operational Efficiency: Achieved a gross margin of 84% despite a slight decrease due to factory clean room expansion.
R&D Expense Reduction: R&D expenses decreased by 44% to $3.3 million compared to Q1 2024.
Strategic Shift: Transitioning to a partnership-focused strategy for nelitolimod, reducing development expenses.
Financial Strategy: Raised $22 million in gross proceeds through a private placement to strengthen the balance sheet.
Macroeconomic Conditions: Management highlighted that forward-looking statements involve material risks and uncertainties, including the impact of macroeconomic conditions and global events that could cause actual results to differ from expectations.
Regulatory Issues: The company mentioned the importance of reimbursement agreements, specifically noting the issuance of a HCPCS code by the Centers for Medicare and Medicaid Services, which is crucial for the adoption of their technology.
Supply Chain Challenges: There was a mention of decreased factory volumes due to a factory clean room expansion, which could impact production capacity.
Financial Performance: The company does not anticipate being EBITDA positive or cash flow positive in 2025, indicating financial challenges ahead.
Partnership Risks: The transition to a partnership-focused strategy for nelitolimod may involve risks related to securing pharmaceutical partnerships and the potential for reduced development expenses.
Market Competition: The company is focused on deepening penetration in the liver embolization market, indicating competitive pressures in this space.
Strategic Initiatives: Growing market share for TriNav in the liver embolization market, advancing technology pipeline, exploring new applications for pressure-enabled drug delivery (PEDD), and preparing nelitolimod for pharmaceutical partnerships.
Key Milestones: Achieved $9.2 million in net sales, a 42% increase compared to Q1 2024, and 11% sequential gain over Q4 2024.
Market Leadership: Positioned as one of the fastest-growing medtech companies in interventional oncology.
Reimbursement Progress: Received HCPCS code C8004 from CMS for mapping procedures using TriNav, doubling reimbursable use.
Product Innovation: Launched TriNav Large and TriGuide, and preparing for the full launch of TriNav Flex.
Clinical Trials: Completed Phase 1 trials for nelitolimod and preparing for potential pharmaceutical partnerships.
Revenue Growth Guidance: Confirmed guidance of at least 50% revenue growth for 2025.
EBITDA Outlook: Do not anticipate being EBITDA positive or cash flow positive in 2025, but expect to be cash flow positive in early 2026.
R&D Spend Reduction: Expect significant reduction in R&D spend in the second half of 2025, with no further spend in 2026.
Financial Position: Raised approximately $22 million in gross proceeds through a private placement to strengthen balance sheet.
Private Placement: Raised approximately $22 million in gross proceeds through a private placement.
Preferred Share Exchange Offer: Reached agreement with 55% of preferred shareholders to implement an exchange offer, converting preferred shares to common stock.
The earnings call reveals solid financial management, with improved cash flow and reduced operating losses. The company's commitment to a 50% growth target and strategic investments in new applications and products support a positive outlook. Despite management's reluctance to provide 2026 guidance, the market strategy and product development updates are favorable. The Q&A highlights robust feedback and growth in new applications, enhancing the sentiment. The positive aspects outweigh the lack of long-term guidance, suggesting a potential stock price increase in the short term.
The earnings call highlighted strong financial performance with a 42% sales increase and a 50% growth guidance for 2025. Product innovations and successful reimbursement progress are positive indicators. Despite operating losses, improved EBITDA and cash position provide stability. The Q&A revealed positive market reception for new products and mapping technology, with strategic investments in sales expected to drive growth. However, uncertainties in partnership discussions and unclear timelines for nelitolimod present some risks. Overall, the positive financials, growth trajectory, and market reception outweigh the uncertainties, suggesting a positive stock price movement.
The earnings call revealed mixed signals: strong revenue growth and reduced losses, but ongoing financial challenges and competitive pressures. The Q&A highlighted positive feedback on products and expansion efforts but also showed management's reluctance to provide clear guidance, raising concerns. The private placement and preferred share exchange offer could dilute stock value. Overall, the company's strategic initiatives and product performance are promising, but financial uncertainties and competitive challenges temper the outlook, resulting in a neutral sentiment.
The earnings call presents a generally positive outlook with strong revenue growth and reduced losses. The Q&A section reveals favorable feedback on new products and strategic initiatives, although some management responses lacked clarity. The strategic partnership focus and cash infusion from a private placement support growth prospects. Despite slight gross margin decline, the overall sentiment remains positive, driven by significant revenue growth and operational improvements. The absence of market cap information limits the prediction's precision, but the positive indicators suggest a stock price increase in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
